|
May 28
|
KMDA vs. CSLLY: Which Stock Should Value Investors Buy Now?
|
|
May 23
|
CSL (ASX:CSL) Secures NICE Approval For Sparsentan Use In NHS England
|
|
May 23
|
England's NICE recommends FILSPARI® (sparsentan) as a treatment option for IgA nephropathy
|
|
May 5
|
CSL (ASX:CSL) Hosts Shareholder Information Meeting for Investor Clarity
|
|
Apr 16
|
Weekly Picks: 🧠 Alphabet’s AI edge, CSL’s pricing power, and a chip underdog
|
|
Apr 13
|
Are CSL Limited's (ASX:CSL) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?
|
|
Mar 3
|
Esperion Partners with CSL Seqirus to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Australia
|
|
Feb 28
|
BMRN or CSLLY: Which Is the Better Value Stock Right Now?
|
|
Feb 20
|
CSL Receives Approval in Japan for ANDEMBRY® (garadacimab) Subcutaneous (S.C.) Injection 200mg Pens, a Novel Human Anti-Activated Factor XII Monoclonal Antibody for the Prevention of Acute Attacks of Hereditary Angioedema (HAE)
|
|
Feb 14
|
Here's What Analysts Are Forecasting For CSL Limited (ASX:CSL) After Its Half-Yearly Results
|
|
Feb 14
|
European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine
|
|
Feb 13
|
European Commission Approves CSL's ANDEMBRY® (garadacimab) for the Prevention of Recurrent Attacks of Hereditary Angioedema (HAE)
|
|
Feb 12
|
BMRN vs. CSLLY: Which Stock Is the Better Value Option?
|
|
Dec 9
|
CSL Behring Scales Global HCP Engagement and Attracts new HCPs with the ON24 Platform
|
|
Oct 2
|
EXEL vs. CSLLY: Which Stock Is the Better Value Option?
|
|
Oct 1
|
CSL Seqirus Presents Real-World Evidence at OPTIONS XII Conference Highlighting Effectiveness of Influenza Vaccinations
|
|
Sep 30
|
Arcturus Therapeutics/CSL Partnered COVID-19 Vaccine Surpasses Pfizer's Comirnaty Shot, Even At Lower Doses
|
|
Sep 30
|
Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination
|
|
Sep 25
|
CSL Seqirus, a Global Leader in Pandemic Preparedness, Announces Fifth BARDA Award in Response to Avian Influenza Outbreak
|
|
Sep 24
|
Veltassa® (patiromer) approved in Japan for the treatment of adults with hyperkalemia
|